Mapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptor

British Journal of Pharmacology

Volumn 159, Issue 2, 2010, Pages 449-461

  Wee, X K ^a   Ng, K S ^a   Leung, H W ^a   Cheong, Y P ^a   Kong, K H ^b   Ng, F M ^a   Soh, W ^a   Lam, Y ^b   Low, Chian Ming ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Amino terminal domain; Benzimidazole; Circular dichroism; GluN2B subunit; Ifenprodil; NMDA receptors; Recombinant protein

Indexed keywords

[N [2 [(4 BENZYLPIPERIDIN 1 YL)METHYL]BENZIMIDAZOL 5 YL]METHANESULFONAMIDE; BENZIMIDAZOLE DERIVATIVE; N [2 (4 PHENOXYBENZYL)BENZIMIDAZOL 5 YL]METHANESULFONAMIDE]; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG; XK 1; XK 2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EMBRYO; IMMUNOCYTOCHEMISTRY; LIGAND BINDING; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; XENOPUS;

ANIMALS; BENZIMIDAZOLES; BINDING SITES; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; HYDROGEN-ION CONCENTRATION; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SULFONAMIDES;

EID: 75649096678     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00549.x     Document Type: Article

References (60)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Birmingham K (2002). Future of neuroprotective drugs in doubt. Nat Med 8 : 5.
3. Borza I, Domány G (2006). NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 6 : 687 695.
4. Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F et al. (1988). Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther 247 : 1222 1232.
5. Cheung NS, Pascoe CJ, Giardina SF, John CA, Beart PM (1998). Micromolar L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurons. Neuropharmacology 37 : 1419 1429.
6. Cheung NS, Koh CH, Bay BH, Qi RZ, Choy MS, Li Q-T et al. (2004). Chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons. Biochem Biophys Res Communs 315 : 408 417.
7. Chernard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL et al. (1995). 1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1- propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 38 : 3138 3145.
8. Chenard BL, Menniti FS (1999). Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 5 : 381 404.
9. 2+]i increases and NMDA receptor mRNA levels. Brain Res 849 : 97 108.
10. Chizh BA, Headley PM, Tzschentke TM (2001). NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharamacol Sci 22 : 636 642.
11. Collingridge GL, Olsen RW, Peters J, Spedding M (2009). A nomenclature for ligand-gated ion channels. Neuropharmacology 56 : 2 5.
12. Dingledine R, Borges K, Bowie D, Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51 : 7 61.
13. Erreger K, Chen PE, Wyllie DJ, Traynelis SF (2004). Glutamate receptor gating. Crit Rev Neurobiol 16 : 187 224.
14. Gitto R, De Luca L, Ferro S, Occhiuto F, Samperi S, De Sarro G et al. (2008). Computational studies to discover a new NR2B/NMDA receptor antagonist and evaluation of pharmacological profile. ChemMedChem 3 : 1539 1548.
15. Gu B, Nakamichi N, Zhang W-S, Nakamura Y, Kambe Y, Fukumori R et al. (2009). Possible protection by notoginsenoside R1 against glutamate toxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly. J Neurosci Res 87 : 2145 2156.
16. Han X, Tomitori H, Mizuno S, Higashi K, Füll C, Fukiwake T et al. (2008). Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor. J Neurochem 107 : 1566 1577.
17. 2+-free solutions in rat cortical neurons in vitro. J Neurochem 68 : 1836 1845.
18. Hocking G, Cousins MJ (2003). Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97 : 1730 1739.
19. Kambe Y, Nakamichi N, Geogiev DD, Nakamura N, Taniura H, Yoneda Y (2008). Insensitivity to glutamate neurotoxicity mediated by NMDA receptors in association with delayed mitochondrial membrane potential disruption in cultured rat cortical neurons. J Neurochem 105 : 1886 1900.
20. Kew JN, Trube G, Kemp JA (1996). A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol (Lond) 497 : 761 772.
21. Kiss L, Cheng G, Bednar B, Bednar RA, Bennett PB, Kane SA et al. (2005). In vitro characterization of novel NR2B selective NMDA receptor antagonists. Neurochem Int 46 : 453 464.
22. Layton ME, Kelly MJ 3rd., Rodzinak KJ (2006). Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr Top Med Chem 6 : 697 709.
23. Le DA, Lipton SA (2001). Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 18 : 717 724.
24. Legendre P, Westbrook GL (1991). Ifenprodil blocks N-methyl-D-aspartate receptors by a two-component mechanism. Mol Pharmacol 40 : 289 298.
25. Li JH, Wang YH, Wolfe BB, Krueger KE, Corsi L, Stocca G et al. (1998). Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons. Eur J Neurosci 10 : 1704 1715.
26. Liu XB, Murray KD, Jones EG (2004). Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci 24 : 8885 8895.
27. Low C-M, Zheng F, Lyuboslavsky P, Traynelis SF (2000). Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc Natl Acad Sci USA 97 : 11062 11067.
28. Low C-M, Lyuboslavsky P, French A, Le P, Wyatte K, Thiel WH et al. (2003). Structural determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol 63 : 1212 1222.
29. McCauley JA, Theberge CR, Romano JJ, Billings SB, Anderson KD, Claremon DA et al. (2004). NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem 47 : 2089 2096.
30. Masuko T, Kashiwagi K, Kuno T, Nguyen ND, Pahk AJ, Fukuchi J et al. (1999). A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol 55 : 957 969.
31. Mizuta I, Katayama M, Watanabe M, Ishii K (1998). Developmental expression of NMDA receptor subunits and the emergence of glutamate neurotoxicity in primary cultures of murine cerebral cortical neurons. Cell Mol Life Sci 54 : 721 725.
32. Mony L, Krzaczkowski L, Leonetti M, Goff AL, Alarcon K, Neyton J et al. (2009a). Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mol Pharmacol 75 : 60 74.
33. Mony L, Kew JNC, Gunthorpe MJ, Paoletti P (2009b). Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanism and therapeutic potential. Br J Pharmacol 157 : 1301 1317.
34. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 : 529 540.
35. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P et al. (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1 : 659 667.
36. Murphy TH, Baraban JM (1990). Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents. Dev Brain Res 57 : 146 150.
37. Ng F-M, Geballe M, Snyder JP, Traynelis SF, Low C-M (2008). Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling students. Mol Brain 1 : 16.
38. Nikam SS, Meltzer LT (2002). NR2B selective NMDA receptor antagonists. Curr Pharm Des 8 : 845 855.
39. Ozawa S, Nakamura T, Yuzaki M (1988). Cation permeability change caused by L-glutamate in cultured rat hippocampal neurons. Brain Res 443 : 85 94.
40. Pahk AJ, Williams K (1997). Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett 225 : 29 32.
41. Paoletti P, Neyton J (2007). NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7 : 9 47.
42. Perin-Dureau F, Rachline J, Neyton J, Paoletti P (2002). Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22 : 5955 5965.
43. Pinard E, Alanine A, Bourson A, Büttelmann B, Heitz M-P, Mutel V et al. (2002). 4-Aminoquinolines as a novel class of NR1/NR2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 12 : 2615 2619.
44. Portera-Cailliau C, Price DL, Martin LJ (1996). N-methyl-D-aspartate receptor proteins NR2A and NR2B are differentially distributed in the developing rat central nervous system as revealed by subunit-specific antibodies. J Neurochem 66 : 692 700.
45. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 : 1333 1341.
46. Rosahl TW, Wingrove PB, Hunt V, Fradley RL, Lawrence JM, Heavens RP et al. (2006). A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor. Mol Cell Neurosci 33 : 47 56.
47. Sans N, Petralia RS, Wang YX, Blahos J 2nd., Hell JW, Wenthold RJ (2000). A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J Neurosci 20 : 1260 1271.
48. 3H] ifenprodil, a novel NMDA antagonist, to a polyamine-sensitive site in the rat cerebral cortex. Eur J Pharmacol 176 : 249 250. (Pubitemid 20041302)
49. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY (1994). Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368 : 144 147.
50. Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL (1998). Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18 : 6163 6175.
51. Wamil AW, McLean MJ (1992). Use-, concentration- and voltage-dependent limitation by MK-801 of action potential firing frequency in mouse central neurons in cell culture. J Pharmacol Exp Ther 260 : 376 383.
52. Wee KS-L, Zhang Y, Khanna S, Low C-M (2008). Immunolocalization of NMDAreceptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cord. J Comp Neurol 509 : 118 135.
53. Williams K (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44 : 851 859.
54. Williams K (2001). Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets 2 : 285 298.
55. Witt A, Macdonald N, Kirkpatrick P (2004). Memantine hydrochloride. Nat Rev Drug Discov 3 : 109 110.
56. Wong ES-P, Ng F-M, Yu C-Y, Lim P, Lim L-H, Traynelis SF et al. (2005). Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor. Protein Sci 14 : 2275 2283.
57. Ying HS, Gottron FJ, Choi DW (2000). Assessment of cell viability in primary neuronal cultures. Curr Protoc Neurosci Chapter 7, Unit 7.18.
58. Yuan H, Erreger K, Dravid SM, Traynelis SF (2005). Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem 280 : 29708 29716.
59. Yuen EY, Ren Y, Yan Z (2008). Postsynaptic density-95 (PSD-95) and calcineurin control the sensitivity of N-methyl-D-aspartate receptors to calpain cleavage in cortical neurons. Mol Pharmacol 74 : 360 370.
60. Zheng F, Erreger K, Low C-M, Banke T, Lee CJ, Conn PJ et al. (2001). Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Nat Neurosci 4 : 894 901.